Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated warning claim is directly supported by the provided FDA label text in section 5.1, including that hepatic VOD (life-threatening and sometimes fatal) has been reported and that patients should be monitored frequently for signs and symptoms of VOD after MYLOTARG.
Category Scores
Accurate Statements
WARNING: HEPATOTOXICITY… including severe or fatal hepatic VOD/SOS… Monitor frequently for signs and symptoms of VOD after MYLOTARG.
Supported by FDA label section 5.1, which states hepatotoxicity including life-threatening and sometimes fatal hepatic VOD events have been reported and instructs to assess ALT/AST/total bilirubin/alkaline phosphatase prior to each dose and to monitor frequently after treatment for signs/symptoms of VOD (e.g., ALT, AST, total bilirubin elevations, hepatomegaly, rapid weight gain, ascites).
Unsupported Statements
Contradictions
Important Omissions
The claim does not mention pre-dose liver laboratory assessment (ALT, AST, total bilirubin, alkaline phosphatase) that the label specifies prior to each dose.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The monitoring warning and severity framing for hepatic VOD (including life-threatening and sometimes fatal outcomes) are supported by label instructions; the main omission is the label’s pre-dose lab assessment detail.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of label-specified pre-dose liver laboratory assessment prior to each dose.
Suggested Improvement
Include the label’s pre-dose assessment language (assess ALT, AST, total bilirubin, and alkaline phosphatase prior to each dose) alongside the post-treatment frequent monitoring instruction.